Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- JCR to Roll Out Cell Therapy Temcell on Feb. 24; Medipal to Be Exclusive Distributor
February 18, 2016
- Genzyme Japan to Be Merged into Sanofi in July
February 17, 2016
- Eisai, Sysmex Link Up in Next-Gen Diagnostic Reagents for Dementia
February 16, 2016
- Shionogi Joins Cambridge Therapeutic Consortium
February 16, 2016
- Asahi Kasei, Pfizer Wind Up Recomodulin Copromotion Scheme
February 16, 2016
- Otsuka’s Pharma Sales Down Nearly 15% in 2015
February 15, 2016
- Pfizer’s Metformin 500 mg Fails to Clear Test, Shipment Suspended
February 15, 2016
- Astellas Completes Acquisition of Ocata
February 15, 2016
- Alecensa Japan PIII Trial Halted Early for Benefit
February 12, 2016
- Lilly’s Japan Sales Slip 2% to US$1.9 Billion in 2015
February 12, 2016
- Sakigake: Now and Future (2) - Shionogi Aims to Submit Application for Novel Flu Drug as Early as FY2017
February 12, 2016
- New CSL Japan Chief Eager to See Annual Sales of 40 Billion Yen in 5 Years
February 10, 2016
- Asahi Kasei President to Step Down over Piling Data Scandal
February 10, 2016
- Daiichi Sankyo to Close UK Development Unit
February 10, 2016
- Otsuka Licenses US Rights for PDE4 Inhibitor to Medimetriks
February 10, 2016
- Ethical Drug Sales Up 5.7% in December: Crecon Report
February 10, 2016
- Gilead, Bristol Take Quantum Leaps in 2015, Lilly Logs Double-Digit Growth: IMS
February 10, 2016
- Japan Sales of “Huge Seller” Quartet Each Break 110 Billion Yen in 2015: IMS
February 10, 2016
- Mundipharma Gearing Up for Full-Blown Oncology Business in Japan
February 9, 2016
- AZ Posts Japan Sales of US$2 Billion in 2015, Down 9% in Actual Terms
February 9, 2016
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…